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Abstract
Background. The ocular adnexal region is the primary lo-
calization of extranodal lymphoma in 5% to 15% of all Non-
Hodgkin lymphoma. Intraocular lymphoma of T-cell origin is
extremely rare and such sites of infiltration have been rarely
observed in clinical examination. Case report. We presented
a 56-year-old man with iris infiltration by primary intraocular
peripheral T-cell lymphoma. The patient was in clinical stage I
BE and the treatment was initiated according to cyclophos-
phamide, hydroxydaunorubicin, oncovin, prednisone
(CHOP) regimen. When the second course of the therapy
was scheduled, the patient developed central nervous system
lymphoma infiltration. Although De Angelis regimen was
used, 3 months after the diagnosis was established, lethal out-
come ensued due to disease progression. Conclusion. Ac-
cording to our experience we can conclude that further
therapeutical approach to patients with primary intraocular T-
cell lymphoma requires modification of conventional treat-
ment regimens. The lower median survival in these patients
suggests that the disease may be of more aggressive course.
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Apstrakt
Uvod. Okularni adneksi su primarna lokalizacija ekstrano-
dalnih limfoma kod 5–15% svih non-Hodgkin limfoma. In-
traokularni limfom T-ćelijskog porekla je redak i u dosadaš-
njoj kliničkoj praksi nije zabeleženo mnogo ovakvih slučaje-
va. Prikaz bolesnika. Prikazali smo bolesnika, starog 56
godina, sa infiltracijom dužice primarnim perifernim T-
ćelijskim limfomom. Bolesnik je inicijalno bio u I BE klinič-
kom stadijumu i započeto je lečenje prema ciklofosfamid,
hidroksidaunorubicin, onkovin, prednizon (CHOP) terapij-
skom protokolu. U terminu kada je zakazan drugi terapijski
ciklus potvrđena je infiltracija centralnog nervnog sistema.
Iako je lečenje nastavljeno prema De Angelis protokolu, do-
šlo je do progresije bolesti i smrtnog ishoda tri meseca na-
kon postavljanja dijagnoze. Zaključak. Na osnovu našeg
iskustva možemo da zaključimo da konvencionalni terapijski
pristup u lečenju bolesnika sa primarnim intraokularnim T-
ćelijskim limfomom zahteva modifikaciju. Niža stopa preži-
vljavanja ovih bolesnika ukazuje na to da bolest može imati
agresivniji tok.
Ključne reči:
limfom, nehodžkinov; dužica, bolesti; dijagnoza;
neoplazme, određivanje stadijuma; histološke tehnike;
lečenje; lečenje, ishod.
Introduction
Neoplasmas may affect the eye orbit as a direct result of
metastatic neoplastic infiltration, compression, or circulating
antibodies involving paraneoplastic retinal degeneration 
1.
Non-Hodgkin lymphoma (NHL) constitute one half of all or-
bital malignancies and ocular adnexa are the primary extra-
nodal lymphoma localization in 5%–15% of all extranodal
NHL 
2. Marginal zone B-cell lymphoma of mucosa associ-
ated lymphoid tissue (MALT) is the most common lym-
phoma category arising in these anatomical structures 
3. In-
traocular lymphoma of T-cell origin is extremely rare and
these sites of infiltration have rarely been observed on clini-
cal examination.
 Lymphomas derived from mature (post-thymic) T-cells
and natural killer (NK) cells, referred to as peripheral T-cell
lymphomas (PTCL), encompass less than 15% of all NHL 
4.
Peripheral T-cell lymphoma, Not Otherwise Specified
(PTCL NOS) is the most common and most heterogenous
category of PTCL. Presentation is usually nodal but any site
can be affected and extranodal involvement is common. The
median age of patients is 70 years, and almost 65% have ad-Strana 1026 VOJNOSANITETSKI PREGLED Volumen 67, Broj 12
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vanced, clinical stage IV of the disease 
4, 5. The most com-
monly used treatment is chemotherapy, the cyclophospha-
mide, hydroxydaunorubicin, oncovin, prednisone (CHOP)
regimen or its variations 
6.
We studied clinical and histopathological findings of a
patient with a very rare iris infiltration by primary intraocular
PTCL NOS.
Case report
A 56-year-old man was admitted at the Institute of He-
matology, Clinical Center of Serbia, with diagnosis of PTCL,
unspecified type, localized in the iris. The diagnosis was
made at the Institute of Ophthalmology in May 2008. The
clinical features included hyperemic right eye with white
membrane in the front segment. On presentation, physical
and laboratory findings were normal without B symptoms
(systemic symptoms of fiver, night sweats and weight loss).
Virusological and bacterial findings, hemostasis of the chest,
X-ray, abdominal ultrasound and bone marrow biopsy were
normal. Computerized tomography (CT) scan of the brain
and paranasal cavities was without pathological findings.
A biopsy of the right eye was performed. Bioptic sam-
ples were analysed according to standard histopathological
(hematoxylin-eosin, Giemsa and Gordon Sweet) and immu-
nohistochemical (Dako LSAB 2 HRP) procedures.
Histopathological evaluation of the iris tissue specimen
showed diffuse tumor infiltration, composed predominantly
of the medium-sized lymphoid cells, and rare single large
lymphoid cells with vesicular nuclei, central prominent nu-
cleoli and scant basophilic cytoplasm (Figure 1 A, B). Im-
munohistochemical studies revealed that tumors cells were
LCA+, TdT-, CD20-, CD3+, CD5+weak, CD43+,
CD45RO+ and CD30- (Figure 1 C–E). Ki-67 was positive in
60% of the tumor cells (Figure 1 F). There was also an in-
flammatory polymorphus background with clustered CD20+
small lymphocytes, rare eosinophils, plasma cells and epi-
theloid histiocytes. The morphologic appearance together
with the immunophenotype of the tumor were diagnostic for
PTCL.
The patients clinical stage was I BE and chemotherapy
(CHOP regimen) was started in June 2008. A month later, at
the time for the second cycle of the CHOP regimen, the pa-
tient was admitted at our Institute in a generally very poor
condition, with a fever (38.4  °C) and neurological symp-
toms: disorientation and left side hemiparesis. Pathological
laboratory findings were mild anemia hemoglobin (Hb) 117
g/L, erythrocyte sedimentation rate (ESR) 28 mm/h, elevated
lactic dehydrogenase (LDH) 620 U/L and elevated C-
reactive protein (CRP) 9,09 mg/L normal range: 0–3 mg/L.
Abdominal ultrasound showed mild hepatomegaly (166
mm). Nuclear magnetic resonance (NMR) of the brain re-
vealed multifocal cortical lesions, lesions of the basal gan-
glias, predominantly periventricular. Although secondary
therapy for central nervous system (CNS) lymphoma local-
ization (De Angelis regimen) was started, the disease had
progressed and the patient died 3 months after the diagnosis
was established.
Figure 1 – (A) Iris tissue samples: diffuse tumor infiltration, composed predominantly of the medium-sized lymphoid cells,
and rare single large lymphoid cells with vesicular nuclei, central prominent nucleoli and scant basophilic cytoplasm (pe-
ripheral T-cell lymphoma; hematoxylin and eosin, ×200); (B) Diffuse tumor infiltration (peripheral T-cell lymphoma;
Giemsa, ×400); (C) The tumor cells negative for CD20 (peripheral T-cell lymphoma, ×400); (D) The tumor cells positive for
CD3 (peripheral T-cell lymphoma, ×400); (E) The tumor cells positive for CD45RO (peripheral T-cell lymphoma, ×400);
(F) The tumor cells positive for Ki67 (peripheral T-cell lymphoma, ×400)Volumen 67, Broj 12 VOJNOSANITETSKI PREGLED Strana 1027
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Discussion
Non Hodgkin lymphoma affects ocular tissues either as
a primary tumor or as a secondary metastasis from systemic
NHL 
1. Intraocular lymphoma is generally of the B-cell type,
similar to NHL elsewhere in the body, whereas T-cell type
lymphoma is quite rare. The intraocular involvement can be
divided into 2 general types 
7. The first is vitreoretinal lym-
phoma, the most common form, associated with CNS lym-
phoma, which is usually of the B-cell type. The second is
uveal lymphoma, which is associated with visceral or nodal
involvement. Between 56% and 85% of patients who ini-
tially present with primary intraocular lymphoma alone will
develop cerebral lesions 
8.
 The appropriate diagnosis of ocular NHL can be made
on identification of malignant cells in the eye by biopsy, but
neuroimaging techniques are fundamental for differential di-
agnosis, staging and evaluation of therapeutic response. The
clinical picture depends on the anatomical sites involved.
Usually, there is a slowly growing, painless mass that dis-
places rather than infiltrates the normal structures, causing an
eyelid lump, ptosis or proptosis 
9–11. In our patient, NHL
simulated uveitis, and there are some papers describing this
as a first NHL sign 
12–16. Some reported cases have been pre-
sented as hypopyon uveitis, neovascular glaucoma, diffuse
iris thickening or as a lymphomatous lesion 
17–19. Our patient
was staged as CSIE with primary iris infiltration, but all
published papers of iris lymphoma describe association with
systemic NHL, and in one case with primary CNS involve-
ment 
15, 18, 19.
Although our patient had no neurological symptoms or
signs on presentation, confirmed with normal brain and
paranasal cavity CT scan, we speculated whether the iris was
the only initial localization because of the very rapid prog-
ress to CNS. Lymphoma brain infiltration was confirmed
with NMR imaging technique month after the patient started
therapy. The routes of infiltration to these specific sites have
already been a topic of research 
20. The lymphoma cells enter
the brain preferentially through the choroids plexus and cra-
nial nerves. Once within the brain, the cells spread and mi-
grate along the optic nerve sheath into the eyes where they
continue to migrate along the choroids, ciliary body, iris, and
into the anterior chamber of the eye. The orbit is also infil-
trated by the lymphoma cells. However, this occurs inde-
pendently of the brain-optic nerve-intraocular route.
The therapeutic strategies for this specific localization
is controversial due to the fact that the primary lymphoma in
the iris, especially of T-cell type, is extremely rare 
6, 21. Or-
bital lymphomas of MALT type show a better prognosis
compared to other lymphoma subtypes arising in the ocular
adnexa. Surgical resection, radiotherapy, and alkylating
agent-based chemotherapy are the standard approaches for
MALT orbital lymphomas 
3. The clinical course of PTCL
lymphomas is aggressive, with frequent relapses and poor
overall outcomes, using conventional management, with a 5-
year overall survival 20%–30% 
6. Many alternate strategies
have been assembled based on retrospective data, small case
series, single institute experience and phase II studies 
21. Un-
fortunately, chemotherapy was not sufficient therapeutic ap-
proach in our patient, we speculated whether local and CNS
prophylactic radiotherapy would have been a better choice.
Radiotherapy could normalize the intraocular pressure fol-
lowed by a reduction in neovascularization of the iris 
22.
Conclusion
Presenting our experience with an unusual ocular site of
PTCL, we conclude that further therapeutical approach re-
quire modification of conventional treatment regimens. The
lower median survival in these patients suggests that the dis-
ease may be prone to a more aggressive course requiring
CNS prophylaxis.
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